Cover Image
Market Research Report
Product code 
915097

Global Tourette Syndrome Market, Size, Share, Opportunities and Forecast, 2020-2027

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Tourette Syndrome Market, Size, Share, Opportunities and Forecast, 2020-2027
Published: April 3, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Global Tourette Syndrome Market is segmented By Treatment Type (Antipsychotic Drugs, Non-Antipsychotic Drugs), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Tourette Syndrome Market is expected to grow at a high CAGR during the forecasting period (2020-2027).

Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements, and vocalizations called tics. The early symptoms of the disease are typically noticed in childhood, with the average onset age of three and nine years. Tourette syndrome occurs in people from all ethnic groups; males are affected about three to four times more often than females. According to National Institute of Neurological Disorders and Stroke, it is estimated that 200,000 Americans have the most severe form of Tourette syndrome, and as many as one in 100 exhibits milder and less complex symptoms such as chronic motor or vocal tics. Although Tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the disease experience their worst tic symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The Tourette syndrome market growth is driven by several factors, such as rise in awareness campaigns, an increase in research and development and robust pipeline.

Many government and non-government organizations are working towards creating awareness among the population about Tourette syndrome. One of these initiatives is a joint effort by Tourette Association of America and Centers for Disease Control and Prevention (CDC) to provide education and awareness on Tourette to various professional audiences, as well as families, individuals, and the general public. The program recently renamed "Tourette Health and Education Program" (THEP) works to expand the ways in which information and education on Tourette are shared. Other organizations, such as Tourettes Action is taking support from social media to increase awareness. On Tourette's Awareness day, the organization asked people to change their profile pictures either with a Tourettes Action twibbon or a TSelfie with one eye blinking as social media is an incredible tool of communication. According to National Institute of Health, the exact incidence of Tourette's syndrome is uncertain, it is estimated to affect 1 to 10 in 1,000 children.

There are currently no commercial approved drug for the treatment of Tourette syndrome in the market. Many companies are working on the research and development of new drugs. The drug pipeline for Tourette syndrome is quite robust, and many drugs are expected to launch during the period of forecast (2020-2027).

Market Pipeline Analysis

Emalex Biosciences is developing new drug Ecopipam (EBS-101) that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette syndrome and stuttering. Emalex is conducting two Phase 2 clinical trials to evaluate the efficacy and safety in patients with Tourette syndrome and stuttering.

Therapix is initiating a Phase IIb clinical trial for THX-110 in two centers in Germany, Hanover, and Munich, which will evaluate the safety and efficacy of THX-110 for the treatment of symptoms of Tourette syndrome. This study is intended to be double-blind, randomized, and placebo-controlled.

Teva Pharmaceuticals, in collaboration with Nuvelution Pharma, Inc. has initiated Phase 3 clinical trial study of AUSTEDO® (deutetrabenazine) for the treatment of tics associated with Tourette syndrome, and the drug is expected to be launched in the period of forecast.

Market Segmentation Analysis

By treatment type, the global Tourette syndrome market is segmented antipsychotic drugs and non-antipsychotic drugs. Antipsychotic drugs are expected to hold the largest market share over the period of forecast (2020-2027) due to their ability to treat tics to a greater extent as compared to non-antipsychotic drugs. Antipsychotic drugs were developed for the treatment of schizophrenia, hence the term antipsychotic. These medications work by blocking another chemical in the brain called dopamine specifically by blocking dopamine receptors, mainly the D2 receptor. Dopamine has been strongly linked with Tourette's syndrome, and some of these drugs are the most useful medications for reducing tics. Fluphenazine, haloperidol (Haldol), risperidone (Risperdal) and pimozide (Orap) are the most commonly used antipsychotic drugs for the treatment of Tourette's syndrome.And these medications are reliably quite effective, but they do have adverse effects that make other forms of medications and other therapies come into existence.

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

North America is dominating the Tourette Syndrome market in 2018 and estimated to hold the largest market size over the forecast period (2020-2027), owing to high incidences of Tourette syndrome, highly aware population, advanced healthcare infrastructure, and favorable government initiatives. One out of 162 children in U.S. have Tourette's Syndrome, and it affects three out of every 1000 children between the age of 6 and 17. Many government and non-government organizations are working towards rising awareness among the common population, such as The American Academy of Neurology (AAN) is the world's largest association of neurologists and neuroscience professionals, with 36,000 members. The AAN is dedicated to promote the highest quality patient-centered neurologic care to Tourette's patients. In 2018, the Labor, Health and Human Services (LHHS) Appropriations Subcommittees and the full Committees on Appropriations in the House and Senate have now both passed FY18 bills - both bills included $2 million in continued funding for the CDC Tourette Syndrome Program.

Source: DataM Intelligence Analysis (2019)

Competitive Landscape

Some of the major key players in the market are H. Lundbeck A/S, Emalex Biosciences, Inc., Teva Pharmaceutical Industries Ltd., Therapix Biosciences Ltd., Neurocrine Bioscience Inc., Eli Lilly and Company, Reviva Pharmaceuticals Inc., Bausch Health Companies Inc., Janssen Pharmaceuticals and Mylan N.V.

In the Tourette Syndrome market, H. Lundbeck A/S holds the leadership position due to robust pipeline, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as new product launches, mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, which are contributing to the growth of the Tourette Syndrome market globally.

In May 2019, H. Lundbeck A/S acquired US biotech company Abide Therapeutics Inc. The acquisition of Abide gives Lundbeck development project of ABX-1431, a first-in-class MAG Lipase inhibitor that is being explored in clinical trials as a first-of-its-kind compound for the treatment of Tourette Syndrome (exploratory phase IIa).

In August 2018, Emalex Biosciences, Inc. announced that it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register, and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome in patients under 16 years of age.

In June 2018, Therapix Biosciences Ltd. sponsored 11th  European Society for the Study of Tourette Syndrome (ESSTS) conference as part of the Company's strategy to develop a therapy for Tourette's patients and to support the Tourette's community.

Why Purchase the Report?

Visualize the composition of the Tourette Syndrome market across each indication, in terms of type and by type highlighting the key commercial assets and players.

Identify commercial opportunities in Tourette Syndrome by analyzing trends and co-development deals.

Excel data sheets with thousands of data points of Tourette Syndrome market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key products of all major market players.

The Global Tourette Syndrome Market report would provide an access to an approx., 16 market data table, 29 figures and 160 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

​​​​​​

Table of Contents

Tourette Syndrome Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Tourette Syndrome Market - Market Definition and Overview

Tourette Syndrome Market - Executive Summary

Market Snippet by Treatment Type

Market Snippet by Region

DataM CLO Scenario

Tourette Syndrome Market Dynamics

Market Impacting Factors

Drivers

Rise in awareness campaigns

Increase in research and development

Robust Pipeline

Restraints

No particular drug targeting the disease

Presence of alternate therapies

Opportunity

Impact Analysis

Tourette Syndrome Market - Industry Analysis

Porter's Five Forces Analysis

Supply Chain Analysis

Regulatory Analysis

Epidemiology

Tourette Syndrome Market - Pipeline Analysis

Tourette Syndrome Market - By Treatment Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market Attractiveness Index, By Treatment Type

Antipsychotic Drugs

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

 Non-Antipsychotic Drugs

Tourette Syndrome Market - By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

U.K.

France

Italy

Spain

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

sia-Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market - Competitive Landscape

Competitive Scenario

Competitor Tourette Syndrome Strategy Analysis

Comparative Product Portfolio Analysis

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Company Profiles

H. Lundbeck A/S*

Company Overview

Product Portfolio and Description

Key Highlights

Financial Overview

Emalex Biosciences, Inc.

Teva Pharmaceutical Industries Ltd.

Therapix Biosciences Ltd.

Neurocrine Bioscience Inc.

Eli Lilly and Company

Reviva Pharmaceuticals Inc.

Bausch Health Companies Inc.

Janssen Pharmaceuticals

Mylan N.V.

Tourette Syndrome Market - Premium Insights

Tourette Syndrome Market - DataM

Appendix

About Us and Services

Contact Us